Brief: Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients
06/02/2025 13:34
Feb 6 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS INC - REPORTS SIGNIFICANT IMPROVEMENT IN
INFLAMMATORY MARKERS IN ALZHEIMER'S PATIENTS
* COYA THERAPEUTICS INC - MONTHLY LD IL-2 SHOWS SIGNIFICANT
REDUCTION IN CCL2 AND IL-15, INCREASE IN IL-4
* COYA THERAPEUTICS INC - LD IL-2 WELL-TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS REPORTED
Source text: ID:nBwbTXTkza
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)